{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T20:47:38Z","timestamp":1760042858156},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s11899-021-00636-2","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T10:02:43Z","timestamp":1621850563000},"page":"336-344","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Emerging Role of Hematopathologists and Molecular Pathologists in Detection, Monitoring, and Management of Myeloid Neoplasms with Germline Predisposition"],"prefix":"10.1007","volume":"16","author":[{"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,24]]},"reference":[{"issue":"20","key":"636_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood."},{"issue":"1","key":"636_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.beha.2014.11.004","volume":"28","author":"DV Babushok","year":"2015","unstructured":"Babushok DV, Bessler M. Genetic predisposition syndromes: when should they be considered in the work-up of MDS? Best Pract Res Clin Haematol. 2015;28(1):55\u201368. https:\/\/doi.org\/10.1016\/j.beha.2014.11.004.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"10","key":"636_CR3","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3324\/haematol.2017.167726","volume":"102","author":"R Kanagal-Shamanna","year":"2017","unstructured":"\u2022 Kanagal-Shamanna R, Loghavi S, DiNardo CD, Medeiros LJ, Garcia-Manero G, Jabbour E, et al. Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica. 2017;102(10):1661 First study to systematically describe the BM morphologic findings in a series of patients with familial predisposition disorders with germline RUNX1 mutation.","journal-title":"Haematologica"},{"issue":"6","key":"636_CR4","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3390\/ijms17060838","volume":"17","author":"SA Bannon","year":"2016","unstructured":"Bannon SA, DiNardo CD. Hereditary predispositions to myelodysplastic syndrome. Int J Mol Sci. 2016;17(6):838.","journal-title":"Int J Mol Sci"},{"issue":"13","key":"636_CR5","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1002\/cncr.31331","volume":"124","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Routbort MJ, Bannon SA, Benton CB, Takahashi K, Kornblau SM, et al. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. Cancer. 2018;124(13):2704\u201313.","journal-title":"Cancer."},{"issue":"22","key":"636_CR6","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1182\/blood-2015-04-641100","volume":"126","author":"JE Churpek","year":"2015","unstructured":"Churpek JE, Pyrtel K, Kanchi KL, Shao J, Koboldt D, Miller CA, et al. Genomic analysis of germ line and somatic variants in familial myelodysplasia\/acute myeloid leukemia. Blood. 2015;126(22):2484\u201390. https:\/\/doi.org\/10.1182\/blood-2015-04-641100.","journal-title":"Blood."},{"key":"636_CR7","doi-asserted-by":"crossref","unstructured":"Feurstein S, Drazer MW, Godley LA. Genetic predisposition to leukemia and other hematologic malignancies. Semin Oncol. 2016;43(5):598\u2013608.","DOI":"10.1053\/j.seminoncol.2016.10.003"},{"issue":"4","key":"636_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2017-02-735290","volume":"130","author":"LA Godley","year":"2017","unstructured":"Godley LA, Shimamura A. Genetic predisposition to hematologic malignancies: management and surveillance. Blood. 2017;130(4):424\u201332.","journal-title":"Blood."},{"issue":"4","key":"636_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.beha.2018.09.014","volume":"31","author":"E Obrochta","year":"2018","unstructured":"Obrochta E, Godley LA. Identifying patients with genetic predisposition to acute myeloid leukemia. Best Pract Res Clin Haematol. 2018;31(4):373\u20138.","journal-title":"Best Pract Res Clin Haematol"},{"key":"636_CR10","doi-asserted-by":"crossref","unstructured":"Kallen ME, Dulau-Florea A, Wang W, Calvo KR. Acquired and germline predisposition to bone marrow failure: Diagnostic features and clinical implications. Semin Hematol. 2019;56(1):69\u201382.","DOI":"10.1053\/j.seminhematol.2018.05.016"},{"issue":"4","key":"636_CR11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.hoc.2018.03.005","volume":"32","author":"EJ Schaefer","year":"2018","unstructured":"Schaefer EJ, Lindsley RC. Significance of clonal mutations in bone marrow failure and inherited myelodysplastic syndrome\/acute myeloid leukemia predisposition syndromes. Hematol Oncol Clin North Am. 2018;32(4):643\u201355.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"636_CR12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1177\/2040620713487399","volume":"4","author":"EM Nickels","year":"2013","unstructured":"Nickels EM, Soodalter J, Churpek JE, Godley LA. Recognizing familial myeloid leukemia in adults. Ther Adv Hematol. 2013;4(4):254\u201369. https:\/\/doi.org\/10.1177\/2040620713487399.","journal-title":"Ther Adv Hematol"},{"key":"636_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/bjh.13838","volume":"175","author":"K Haslam","year":"2015","unstructured":"Haslam K, Langabeer SE, Hayat A, Conneally E, Vandenberghe E. Targeted next-generation sequencing of familial platelet disorder with predisposition to acute myeloid leukaemia. Br J Haematol. 2015;175:161\u20133. https:\/\/doi.org\/10.1111\/bjh.13838.","journal-title":"Br J Haematol"},{"issue":"10","key":"636_CR14","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/ajmg.a.37870","volume":"170","author":"SR Braddock","year":"2016","unstructured":"Braddock SR, South ST, Schiffman JD, Longhurst M, Rowe LR, Carey JC. Braddock\u2013Carey syndrome: a 21q22 contiguous gene syndrome encompassing RUNX1. Am J Med Genet A. 2016;170(10):2580\u20136.","journal-title":"Am J Med Genet A"},{"issue":"9","key":"636_CR15","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1038\/s41379-020-0531-2","volume":"33","author":"AE Quesada","year":"2020","unstructured":"Quesada AE, Montalban-Bravo G, Luthra R, Patel KP, Sasaki K, Bueso-Ramos CE, et al. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol. 2020;33(9):1678\u201389. https:\/\/doi.org\/10.1038\/s41379-020-0531-2.","journal-title":"Mod Pathol"},{"issue":"4","key":"636_CR16","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/leu.2015.236","volume":"30","author":"I Antony-Debre","year":"2016","unstructured":"Antony-Debre I, Duployez N, Bucci M, Geffroy S, Micol J, Renneville A, et al. Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia. Leukemia. 2016;30(4):999\u20131002.","journal-title":"Leukemia."},{"issue":"12","key":"636_CR17","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1182\/blood-2014-01-550525","volume":"124","author":"JP Connelly","year":"2014","unstructured":"Connelly JP, Kwon EM, Gao Y, Trivedi NS, Elkahloun AG, Horwitz MS, et al. Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects. Blood. 2014;124(12):1926\u201330.","journal-title":"Blood"},{"issue":"6","key":"636_CR18","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1182\/bloodadvances.2019000901","volume":"4","author":"AL Brown","year":"2020","unstructured":"Brown AL, Arts P, Carmichael CL, Babic M, Dobbins J, Chong C-E, et al. RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Adv. 2020;4(6):1131\u201344.","journal-title":"Blood Adv"},{"issue":"11","key":"636_CR19","doi-asserted-by":"publisher","first-page":"E313","DOI":"10.1002\/ajh.25965","volume":"95","author":"C Lachowiez","year":"2020","unstructured":"Lachowiez C, Bannon S, Loghavi S, Wang F, Kanagal-Shamanna R, Mehta R, et al. Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. Am J Hematol. 2020;95(11):E313\u2013E5.","journal-title":"Am J Hematol"},{"key":"636_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13023-016-0432-0","volume":"11","author":"V Latger-Cannard","year":"2016","unstructured":"Latger-Cannard V, Philippe C, Bouquet A, Baccini V, Alessi MC, Ankri A, et al. Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders. Orphanet J Rare Dis. 2016;11:49. https:\/\/doi.org\/10.1186\/s13023-016-0432-0.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"636_CR21","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1097\/MPH.0b013e31821754ac","volume":"33","author":"V Latger-Cannard","year":"2011","unstructured":"Latger-Cannard V, Philippe C, Jonveaux P, Lecompte T, Favier R. Dysmegakaryopoiesis, a clue for an early diagnosis of familial platelet disorder with propensity to acute myeloid leukemia in case of unexplained inherited thrombocytopenia associated with normal-sized platelets. J Pediatr Hematol Oncol. 2011;33(7):e264\u2013e6.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"636_CR22","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/modpathol.2016.218","volume":"30","author":"HC Tsang","year":"2017","unstructured":"\u2022 Tsang HC, Bussel JB, Mathew S, Liu Y-C, Imahiyerobo AA, Orazi A, et al. Bone marrow morphology and disease progression in congenital thrombocytopenia: a detailed clinicopathologic and genetic study of eight cases. Mod Pathol. 2017;30(4):486\u201398 Study demonstrates megakaryocytic abnormalities in patients with germline predisposition disorders including those outside of the 2016 WHO classification by bone marrow morphologic evaluation.","journal-title":"Mod Pathol"},{"issue":"13","key":"636_CR23","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1182\/blood-2012-04-422337","volume":"120","author":"D Bluteau","year":"2012","unstructured":"Bluteau D, Glembotsky AC, Raimbault A, Balayn N, Gilles L, Rameau P, et al. Dysmegakaryopoiesis of FPD\/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression. Blood. 2012;120(13):2708\u201318.","journal-title":"Blood"},{"issue":"23","key":"636_CR24","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1182\/blood-2016-03-378588","volume":"127","author":"C Lentaigne","year":"2016","unstructured":"Lentaigne C, Freson K, Laffan MA, Turro E, Ouwehand WH. Inherited platelet disorders: toward DNA-based diagnosis. Blood. 2016;127(23):2814\u201323.","journal-title":"Blood"},{"issue":"12","key":"636_CR25","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1111\/jth.13855","volume":"15","author":"C Zaninetti","year":"2017","unstructured":"Zaninetti C, Santini V, Tiniakou M, Barozzi S, Savoia A, Pecci A. Inherited thrombocytopenia caused by ANKRD 26 mutations misdiagnosed and treated as myelodysplastic syndrome: report on two cases. J Thromb Haemost. 2017;15(12):2388\u201392.","journal-title":"J Thromb Haemost"},{"key":"636_CR26","doi-asserted-by":"crossref","first-page":"232470962093894","DOI":"10.1177\/2324709620938941","volume":"8","author":"T Kewan","year":"2020","unstructured":"Kewan T, Noss R, Godley LA, Rogers HJ, Carraway HE. Inherited thrombocytopenia caused by germline ANKRD26 mutation should be considered in young patients with suspected myelodysplastic syndrome. J Investig Med High Impact Case Rep. 2020;8:2324709620938941.","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"1","key":"636_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000490311","volume":"86","author":"JT Geyer","year":"2019","unstructured":"Geyer JT. Myeloid neoplasms with germline predisposition. Pathobiology. 2019;86(1):53\u201361.","journal-title":"Pathobiology."},{"key":"636_CR28","doi-asserted-by":"crossref","unstructured":"\u2022 Simon L, Spinella JF, Yao CY, Lavall\u00e9e VP, Boivin I, Boucher G, Audemard E, Bordeleau ME, Lemieux S, H\u00e9bert J, Sauvageau G. High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML. Blood. 2020;135(21):1882\u20131886 Recent study that shows that up to 30% of RUNX1 mutations in a defined AML cohort to be of germline origin, emphasizing the need for high suspicion. The study also shows distinct patterns of somatic mutations between AML with somatic versus germline RUNX1 mutations.","DOI":"10.1182\/blood.2019003357"},{"issue":"3","key":"636_CR29","doi-asserted-by":"publisher","first-page":"a026286","DOI":"10.1101\/cshperspect.a026286","volume":"7","author":"EQ Comeaux","year":"2017","unstructured":"Comeaux EQ, Mullighan CG. TP53 mutations in hypodiploid acute lymphoblastic leukemia. Cold Spring Harb Perspect Med. 2017;7(3):a026286.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"636_CR30","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2017.75.5215","volume":"36","author":"M Qian","year":"2018","unstructured":"Qian M, Cao X, Devidas M, Yang W, Cheng C, Dai Y, et al. TP53 germline variations influence the predisposition and prognosis of B-cell acute lymphoblastic leukemia in children. J Clin Oncol. 2018;36(6):591\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"636_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-019-1193-1","volume":"21","author":"F Batalini","year":"2019","unstructured":"Batalini F, Peacock EG, Stobie L, Robertson A, Garber J, Weitzel JN, et al. Li-Fraumeni syndrome: not a straightforward diagnosis anymore\u2014the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis. Breast Cancer Res. 2019;21(1):1\u201310.","journal-title":"Breast Cancer Res"},{"key":"636_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1200\/PO.19.00279","volume":"4","author":"EG Peacock","year":"2020","unstructured":"Peacock EG, Grenon LM, Batalini F, Tung N. Challenges in interpreting TP53 pathogenic variants with a low minor allele frequency in germline genetic testing: a case report of a patient with mosaic Li-Fraumeni syndrome. JCO Precis Oncol. 2020;4:91\u20135.","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"636_CR33","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.ccell.2015.03.017","volume":"27","author":"C Polprasert","year":"2015","unstructured":"\u2022 Polprasert C, Schulze I, Sekeres MA, Makishima H, Przychodzen B, Hosono N, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell. 2015;27(5):658\u201370 The key study that identified familial AML syndrome with DDX41 germline mutation, often seen in combination with a somatic DDX41 mutation, constituting a family of tumor suppressor genes.","journal-title":"Cancer Cell"},{"issue":"12","key":"636_CR34","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1080\/17474086.2016.1257936","volume":"9","author":"N Duployez","year":"2016","unstructured":"Duployez N, Lejeune S, Renneville A, Preudhomme C. Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologists. Expert Rev Hematol. 2016;9(12):1189\u2013202.","journal-title":"Expert Rev Hematol"},{"issue":"17","key":"636_CR35","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1182\/blood.2019000909","volume":"134","author":"M S\u00e9bert","year":"2019","unstructured":"S\u00e9bert M, Passet M, Raimbault A, Rahm\u00e9 R, Raffoux E. Sicre de Fontbrune F et al. Germline DDX41 mutations define a significant entity within adult MDS\/AML patients. Blood. 2019;134(17):1441\u20134.","journal-title":"Blood."},{"issue":"7","key":"636_CR36","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ajh.25486","volume":"94","author":"AE Quesada","year":"2019","unstructured":"Quesada AE, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Khoury JD, et al. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol. 2019;94(7):757\u201366.","journal-title":"Am J Hematol"},{"issue":"8","key":"636_CR37","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1182\/blood-2015-10-676098","volume":"127","author":"M Lewinsohn","year":"2016","unstructured":"Lewinsohn M, Brown AL, Weinel LM, Phung C, Rafidi G, Lee MK, et al. Novel germ line DDX41 mutations define families with a lower age of MDS\/AML onset and lymphoid malignancies. Blood. 2016;127(8):1017\u201323.","journal-title":"Blood."},{"issue":"Supplement 1","key":"636_CR38","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1182\/blood-2018-99-116518","volume":"132","author":"S Bannon","year":"2018","unstructured":"Bannon S, Routbort M, Garcia-Manero G, Daver NG, Oran B, Borthakur G, et al. Next-generation sequencing of DDX41 in myeloid neoplasms leads to increased detection of germline alterations. Blood. 2018;132(Supplement 1):2667.","journal-title":"Blood"},{"issue":"4","key":"636_CR39","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41588-019-0375-1","volume":"51","author":"I Iacobucci","year":"2019","unstructured":"Iacobucci I, Wen J, Meggendorfer M, Choi JK, Shi L, Pounds SB, et al. Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nat Genet. 2019;51(4):694\u2013704.","journal-title":"Nat Genet"},{"key":"636_CR40","doi-asserted-by":"crossref","unstructured":"Maciejewski JP, Padgett RA, Brown AL, M\u00fcller-Tidow C. DDX41-related myeloid neoplasia. Semin Hematol. 2017;54(2):94\u201397.","DOI":"10.1053\/j.seminhematol.2017.04.007"},{"issue":"2","key":"636_CR41","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ajh.25610","volume":"95","author":"I Abou Dalle","year":"2020","unstructured":"Abou Dalle I, Kantarjian H, Bannon SA, Kanagal-Shamanna R, Routbort M, Patel KP, et al. Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. Am J Hematol. 2020;95(2):227\u20139.","journal-title":"Am J Hematol"},{"issue":"12","key":"636_CR42","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1038\/leu.2016.228","volume":"30","author":"E Negoro","year":"2016","unstructured":"Negoro E, Radivoyevitch T, Polprasert C, Adema V, Hosono N, Makishima H, et al. Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. Leukemia. 2016;30(12):2405\u20139.","journal-title":"Leukemia."},{"issue":"20","key":"636_CR43","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/bloodadvances.2019000644","volume":"3","author":"X Luo","year":"2019","unstructured":"\u2022 Luo X, Feurstein S, Mohan S, Porter CC, Jackson SA, Keel S, et al. ClinGen myeloid malignancy variant curation expert panel recommendations for germline RUNX1 variants. Blood Adv. 2019;3(20):2962\u201379 ClinGen myeloid malignancy variant curation expert panel developed RUNX1-specific curation rules that can guide in RUNX1 variant classification and uniform interpretation across the institutions. The study showed that applying the rules resulted in a significant reduction of variants of uncertain significance.","journal-title":"Blood Adv"},{"issue":"4","key":"636_CR44","doi-asserted-by":"publisher","first-page":"870","DOI":"10.3324\/haematol.2018.214221","volume":"105","author":"D Wu","year":"2020","unstructured":"Wu D, Luo X, Feurstein S, Kesserwan C, Mohan S, Pineda-Alvarez DE, et al. How I curate: applying American Society of Hematology-Clinical Genome Resource Myeloid Malignancy Variant Curation Expert Panel rules for RUNX1 variant curation for germline predisposition to myeloid malignancies. Haematologica. 2020;105(4):870\u201387.","journal-title":"Haematologica."},{"issue":"24","key":"636_CR45","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1038\/sj.onc.1207779","volume":"23","author":"M Osato","year":"2004","unstructured":"Osato M. Point mutations in the RUNX1\/AML1 gene: another actor in RUNX leukemia. Oncogene. 2004;23(24):4284\u201396.","journal-title":"Oncogene."},{"issue":"9","key":"636_CR46","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1038\/s41375-020-0752-x","volume":"34","author":"EC DiFilippo","year":"2020","unstructured":"DiFilippo EC, Coltro G, Carr RM, Mangaonkar AA, Binder M, Khan SP, et al. Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS\/MPN overlap neoplasms. Leukemia. 2020;34(9):2519\u201324.","journal-title":"Leukemia."},{"issue":"6","key":"636_CR47","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1182\/blood-2013-07-515528","volume":"123","author":"MA Spinner","year":"2014","unstructured":"Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, Calvo KR, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood. 2014;123(6):809\u201321.","journal-title":"Blood."},{"issue":"10","key":"636_CR48","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1182\/blood-2011-05-356352","volume":"118","author":"AP Hsu","year":"2011","unstructured":"Hsu AP, Sampaio EP, Khan J, Calvo KR, Lemieux JE, Patel SY, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood. 2011;118(10):2653\u20135.","journal-title":"Blood."},{"issue":"8","key":"636_CR49","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3324\/haematol.2017.181909","volume":"103","author":"J Donadieu","year":"2018","unstructured":"Donadieu J, Lamant M, Fieschi C, de Fontbrune FS, Caye A, Ouachee M, et al. Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. Haematologica. 2018;103(8):1278\u201387.","journal-title":"Haematologica."},{"key":"636_CR50","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/ijlh.12999","volume":"41","author":"P Galera","year":"2019","unstructured":"Galera P, Dulau-Florea A, Calvo KR. Inherited thrombocytopenia and platelet disorders with germline predisposition to myeloid neoplasia. Int J Lab Hematol. 2019;41:131\u201341.","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"636_CR51","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1182\/blood.2019000937","volume":"136","author":"AL Brown","year":"2020","unstructured":"Brown AL, Hahn CN, Scott HS. Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA). Blood. 2020;136(1):24\u201335.","journal-title":"Blood"},{"issue":"18","key":"636_CR52","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1182\/blood-2018-07-861070","volume":"132","author":"P Galera","year":"2018","unstructured":"Galera P, Hsu AP, Wang W, Droll S, Chen R, Schwartz JR, et al. Donor-derived MDS\/AML in families with germline GATA2 mutation. Blood. 2018;132(18):1994\u20138.","journal-title":"Blood."},{"issue":"10","key":"636_CR53","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/ng.913","volume":"43","author":"CN Hahn","year":"2011","unstructured":"Hahn CN, Chong CE, Carmichael CL, Wilkins EJ, Brautigan PJ, Li XC, et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet. 2011;43(10):1012\u20137. https:\/\/doi.org\/10.1038\/ng.913.","journal-title":"Nat Genet"},{"key":"636_CR54","doi-asserted-by":"crossref","unstructured":"Sahoo SS, Kozyra EJ, Wlodarski MW. Germline predisposition in myeloid neoplasms: Unique genetic and clinical features of GATA2 deficiency and SAMD9\/SAMD9L syndromes. Best Pract Res Clin Haematol. 2020;33(3):101197.","DOI":"10.1016\/j.beha.2020.101197"},{"issue":"3","key":"636_CR55","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/ajcp\/aqz067","volume":"152","author":"OK Weinberg","year":"2019","unstructured":"Weinberg OK, Kuo F, Calvo KR. Germline predisposition to hematolymphoid neoplasia: 2017 Society for Hematopathology\/European Association for Haematopathology workshop report. Am J Clin Pathol. 2019;152(3):258\u201376.","journal-title":"Am J Clin Pathol"},{"key":"636_CR56","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.leukres.2018.11.013","volume":"76","author":"LJ McReynolds","year":"2019","unstructured":"McReynolds LJ, Yang Y, Wong HY, Tang J, Zhang Y, Mul\u00e9 MP, et al. MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations. Leuk Res. 2019;76:70\u20135.","journal-title":"Leuk Res"},{"issue":"1","key":"636_CR57","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1182\/blood-2014-06-580340","volume":"125","author":"KA Ganapathi","year":"2015","unstructured":"Ganapathi KA, Townsley DM, Hsu AP, Arthur DC, Zerbe CS, Cuellar-Rodriguez J, et al. GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia. Blood. 2015;125(1):56\u201370.","journal-title":"Blood."}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00636-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-021-00636-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00636-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T02:40:01Z","timestamp":1699065601000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-021-00636-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,24]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["636"],"URL":"https:\/\/doi.org\/10.1007\/s11899-021-00636-2","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,24]]},"assertion":[{"value":"19 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}